Table 1 Demographic and clinical features of study participants
From: A peripheral signature of Alzheimer’s disease featuring microbiota-gut-brain axis markers
CU | CI-NAD | CI-AD | P-value | ||
|---|---|---|---|---|---|
ANOVA b | CI-NAD vs CI-AD c | ||||
N | 13 | 38 | 34 | ||
Age (years) | 69.6 (7.1) | 69.8 (7.4) | 70.8 (6.1) | .796 | > .999 |
Female | 7 (54%) | 21 (55%) | 16 (47%) | .775 | .487 |
Education (years) | 9.1 (5.2) | 8.5 (3.9) | 8.7 (4.5) | > .999 | > .999 |
Body mass indexa | 25.0 (3.4) | 25.3 (3.8) | 24.9 (2.9) | > .999 | > .999 |
APOEe4 carrier statusd | 2 (18%) | 3 (9%) | 20 (65%) | < .001 | < .001 |
General cognition | |||||
Mini-Mental State Examination | 28.3 (1.2) | 24.8 (3.9) | 22.2 (5.1) | < .001 | 0.101 |
ADAScog | 8.2 (3.3) | 15.3 (9.5) | 17.1 (7.6) | < .001 | .330 |
Clinical stage | |||||
Mild cognitive impairment | - | 21 (55%) | 22 (65%) | .415 | |
Dementia | - | 17 (45%) | 12 (35%) | .415 | |
Amyloid load (PET SUVr) | .95 (.07) | .92 (.09) | 1.31 (.13) | < .001 | < .001 |